SCHEMBL3108359

SCHEMBL3108359

CCc1cc(-c2nc(-c3ccc(C(C)(C)C)cc3)no2)nn1Cc1ccc(C)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.51
RAB9A P51151 5/20 0.51
ALDH1A1 P00352 1/20 0.51
S1PR4 O95977 3/20 0.46
S1PR1 P21453 3/20 0.46
S1PR5 Q9H228 3/20 0.46
S1PR3 Q99500 2/20 0.46
MAPT P10636 6/20 0.45
KDM4E B2RXH2 2/20 0.43
TP53 P04637 2/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HDAC3 O15379 2/20 0.42
HDAC4 P56524 2/20 0.42
HDAC1 Q13547 2/20 0.42
HDAC7 Q8WUI4 2/20 0.42
HDAC2 Q92769 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3094824 0.91 STAT3 (0.51) NPC1RAB9AS1PR1S1PR3MAPT
SCHEMBL3102030 0.89 NPC1 (0.54) NPC1RAB9AALDH1A1S1PR4S1PR1
SCHEMBL14025119 0.88 NR1H4 (0.44) NPC1RAB9AALDH1A1S1PR1MAPT
SCHEMBL3095125 0.88 MAPT (0.48) NPC1RAB9AALDH1A1S1PR1MAPT
SCHEMBL3102649 0.84 STAT3 (0.44) NPC1RAB9AS1PR1MAPTTP53
SCHEMBL3103041 0.83 P2RY14 (0.44) NPC1RAB9AALDH1A1MAPTTP53
SCHEMBL3090982 0.82 HDAC3 (0.51) NPC1RAB9AALDH1A1S1PR4S1PR1
SCHEMBL3089605 0.82 MEN1 (0.48) RAB9AMAPTLMNATSHRHDAC3
SCHEMBL13363438 0.81 NPC1 (0.53) NPC1RAB9AALDH1A1S1PR4S1PR1
SCHEMBL3091102 0.80 HDAC3 (0.48) NPC1RAB9AALDH1A1S1PR4S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796253-B2 Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-08-05 US disclosed
US-8796253-B2 Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-08-05 US disclosed
US-8796253-B2 Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-08-05 US disclosed
US-20100249085-A1 HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-09-30 US disclosed
US-20100249085-A1 HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249085-A1 HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS FLT4, VEGFA, MKI67 NPC1 1028/4885RAB9A 1563/4885ALDH1A1 1552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.